

Remarks***Restriction Requirement:***

The Examiner telephoned Applicant and the parties further discussed the restriction requirement set forth in the Office Action of November 1, 2004. Applicant has amended the claims in accordance with her understanding of Examiner's verbal instructions concerning the restrictions requirement. Applicant has reinstated the original definitions for R1, R2, and R4 per Examiner's request. Also, pursuant to Examiner's request, R3 has been limited to $(CH_2)_n$ Q, $CH_2CH(OH)Q$, $CH(CH_3)Q$, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl or furanyl, and

Q is optionally substituted with one or two moieties independently selected from halo,

C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, $S(O)_2NH_2$, trifluoromethyl, or cyano, and

n is 1 or 2.

The Applicant has reinstated the process claims after amending said claims so as to correspond with the revised Group set forth by the Examiner. Finally, certain species that were previously withdrawn because they fell outside the scope of the original restriction requirement have been "reinstated" in view of the revised Group set forth by the Examiner.

Conclusion:

In view of the above, Applicant believes the application is now in condition for allowance.

Respectfully submitted,



Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. HMR2023US PCT